Enabling Broader Adoption Of Process Intensification In Biopharma
Source: Sartorius
By Ganesh Kumar, Sartorius

PI is becoming increasingly well-understood and its utility is continuously evolving to meet specific manufacturer needs, from product development to manufacturing, whether approached stepwise or end-to-end.
The benefits of process intensification (PI) in biopharmaceutical manufacturing are well established: PI enables manufacturers to increase volumetric productivity, reduce timelines, decrease facility footprint, lower costs, or improve flexibility. However, knowledge about PI implementation — from the costs to the technological and regulatory aspects, and risk mitigation — is less ubiquitous.
VIEW THE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of BioProcess Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Sartorius
This website uses cookies to ensure you get the best experience on our website. Learn more